Induction of cytostasis in mammary carcinoma cells treated with the anticancer agent perillyl alcohol

Carcinogenesis

Volumn 23, Issue 1, 2002, Pages 131-142

  Shi, Wenge ^b   Gould, Michael N ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D1; CYCLIN DEPENDENT KINASE 2; CYCLIN E; PERILLYL ALCOHOL; PROTEIN P21; RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CARCINOMA; CANCER INHIBITION; CARCINOMA CELL; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL PROLIFERATION; CELL TRANSFORMATION; COMPLEX FORMATION; CONTROLLED STUDY; CYTOSTASIS; ENZYME PHOSPHORYLATION; IN VITRO STUDY; MAMMAL CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL;

EID: 0036195294     PISSN: 01433334     EISSN: None     Source Type: Journal    
DOI: 10.1093/carcin/23.1.131     Document Type: Article

References (52)

1. Chemoprevention and therapy of cancer by D-limonene
2. Cancer chemoprevention and therapy by monoterpenes
3. Phase I and pharmacokinetic study of D-limonene in patients with advanced cancer
4. Phase I clinical trial of perillyl alcohol administered daily
5. Phase I clinical and pharmacokinetic study of perillyl alcohol administered four times a day
6. Effects of monoterpenoids on in vivo DMBA-DNA adduct formation and on phase I hepatic metabolizing enzymes
7. The chemoprevention of cancer by mevalonate-derived constituents of fruits and vegetables
8. Selective inhibition of isoprenylation of 21-26-kDa proteins by the anticarcinogen D-limonene and its metabolites
9. Prenylated proteins and lymphocyte proliferation: Inhibition by d-limonene related monoterpenes
10. Structure-activity relationships among monoterpene inhibitors of protein isoprenylation and cell proliferation
11. Inhibition of ubiquinone and cholesterol synthesis by the monoterpene perillyl alcohol
12. Identifying differential gene expression in monoterpene-treated mammary carcinomas using subtractive display
13. Activation of the transforming growth factor beta signaling pathway and induction of cytostasis and apoptosis in mammary carcinomas treated with the anticancer agent perillyl alcohol
14. 125l-insulin-like growth factor II degradation by modulating the process
15. Increased mannose 6-phosphate/insulin-like growth factor II receptor and transforming growth factor beta 1 levels during monoterpene-induced regression of mammary tumors
16. Induction of apoptosis in liver tumors by the monoterpene perillyl alcohol
17. Chemoprevention of colon carcinogenesis by dietary perillyl alcohol
18. Cancer cell cycles
19. The retinoblastoma protein and cell cycle control
20. E2F: A link between the Rb tumor suppressor protein and viral oncoproteins
21. The regulation of E2F by pRB family protein
22. Principles of CDK regulation
23. 1 cyclin-dependent kinases
24. Tumor suppressor genes
25. 1-phase progression
26. New functional activities for the p21 family of CDK inhibitors
27. p21 is a critical CDK2 regulator essential for proliferation control in Rb-deficient cells
28. Differential interaction of the cyclin-dependent kinase (Cdk) inhibitor p27Kip1 with cyclin A-Cdk2 and cyclin D2-Cdk4
29. Regulation of CDKs by phosphorylation
30. Both p16 and p21 families of cyclin-dependent kinase (CDK) inhibitors block the phosphorylation of cyclin-dependent kinases by the CDK-activating kinase
31. Cloning of p27Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals
32. Morphological and functional properties of TM preneoplastic mammary outgrowths
33. p53 mutations in, D cells
34. Immunoprecipitation and immunoblotting in cell cycle studies
35. p21WAF1/CIP1/SDI1 is elevated through a p53-independent pathway by mimosine
36. A reversible arrest point in the late G1 phase of the mammalian cell cycle
37. Mimosine reversibly arrests cell cycle progression at the G1-S phase border
38. Cell cycle regulation of CDK2 activity by phosphorylation of Thr160 and Tyr15
39. Cell cyclins and cyclin-dependent kinase activities in mouse mammary tumor development
40. Mammary carcinoma regression induced by perillyl alcohol, a hydroxylated analog of limonene
41. p21Waf1 inhibits the activity of cyclin dependent kinase 2 by preventing its activating phosphorylation
42. Inhibition of type I and type II geranylgeranyl-protein transferases by the monoterpene perillyl alcohol in NIH3T3 cells
43. Inhibition of the 3-hydroxy-3-methylglutaryl-coenzyme A reductase pathway induces p53-independent transcriptional regulation of p21 (WAF1/CIP1) in human prostate carcinoma cells
44. The geranylgeranyltransferase-I inhibitor GGTI-298 arrests human tumor cells in G0/G1 and induces p21 (WAF1/CIP1/SDI1) in a p53-independent manner
45. Signals from Ras and Rho GTPases interact to regulate expression of p21Waf1/Cip1
46. p21 (WAF1/Cip1) is upregulated by the geranylgeranyltransferase inhibitor GGTI-298 through a transforming growth factor Beta- and Sp1-responsive element-involvement of the small GTPase RhoA
47. D-type cyclin-dependent kinase activity in mammalian cells
48. Cell cycle start from quiescence controlled by tyrosine phosphorylation of Cdk4
49. Requirement for tyrosine phosphorylation of Cdk4 in G1 arrest induced by ultraviolet irradiation
50. Repression of the CDK activator Cdc25A and cell-cycle arrest by cytokine TGF-beta in cells lacking the CDK inhibitor p15
51. Active cdk6 complexes are predominantly nuclear and represent only a minority of the cdk6 in T cells
52. Lack of relationship between CDK activity and G1 cyclin expression in breast cancer cells